The Third International Conference on Regulatory T cells and Th Subsets and Clinical Application in Human Diseases was held in Shanghai, China during 13 -15 October 2012. This conference, organized by Shuiping Jiang, the Conference Founder and President, and Xuetao Cao, the President of Chinese Society for Immunology, brought together many prominent experts in the field of regulatory T cells (Tregs) and T helper cells (Th) subsets immunology and highlighted the cutting-edge advancements on the development, function, homeostasis and interplay of Tregs and Th subsets, especially the latest breakthrough in therapeutic applications in clinical settings.
The balance between effector and regulatory factors in immune system is essential to prevent tissue damage during infection and control excessive or self-destructive responses. It has been proved that Tregs, characterized by the expression of transcriptional factor FoxP3, as a 'brake', play key roles in blocking immune responses, inflammation and tissue destruction by suppressing the functions of multiple cell types (Zhou et al., 2009) . In contrast, effector cells mediate the development and pathogeneses of infections, autoimmune diseases, tumors and transplantation rejections. Apart from conventional Th1 and Th2 cells, the newly discovered T helper cell subsets, including Th17, Th9, Th22, T follicular helper cells and innate lymphoid cells, also produce inflammatory cytokines, such as IL-17, IL-9 and IL-22. Regulating the function of these T effectors may be helpful in developing novel therapeutic strategies.
Given In this session, multiple subclasses of antigen-specific T follicular helper (T FH ) cells were found to exert different roles in controlling the facets of high-affinity classspecific B cell memory.
As plenty of studies have demonstrated the therapeutic efficacy of Tregs in animal disease models, adoptive transfer of human Tregs may represent a promising cellular therapy for the treatment of autoimmune diseases, transplantation rejections and inflammatory diseases. Three trials of Tregs therapy for graft-versus-host disease (GvHD) in patients have revealed its efficacy in transplantation (Tang et al., 2012) . Qizhi Tang from University of California at San Francisco emphasized three key points in transplantation tolerance, including the reduction of donorspecific T cells, induction of more effective donor-reactive Tregs than polyclone Tregs, and aborting CTL effector responses in allograft. Bruce Blazar at University of Minnesota presented the potential efficacy of using ex vivo expanded natural and inducible Tregs for the prevention of GvHD.
In addition, new signaling targets for modulating Tregs or effector T cell function can be employed for developing novel therapeutic strategies by either increasing suppressive function of Tregs in transplantation and autoimmune diseases, or blocking Tregs and boosting T effector cells in tumors. For example, low dose of IL-2 has been reported to lead to Tregs recovery and concomitant clinical improvement in patients with HCV-induced vasculitis (Saadoun et al., 2011) . In this meeting, Yong-Jun Liu (University of Texas M.D. and Baylor Research Institute) and colleagues demonstrated that HDACI-induced OX40L inhibited the generation of IL-10-producing type 1 Tregs, providing an anti-tumor response in patients. Yong-Jun Liu further illustrated that humanized agonist mAb to human OX40 promoted effector T cell function and blocked the function of both iTregs and nTregs.
Two scientists Jun Yan (University of Louisville) and Yuping Lai (East China Normal University) presented the role of IL-17 in regulating psoriasis pathogenesis. Therefore, targeting and modulating cellular responses to IL-17 could be beneficial in certain types of IL-17 mediated diseases. In two recent Phases 2 clinical trials, anti-IL-17 and anti-IL-17 receptor antibodies indicated significant improvement of the clinical symptoms of psoriasis Papp et al., 2012) , which further illustrated the role of IL-17 in human autoimmune and inflammatory diseases. These findings substantiate the therapeutic strategy for immune diseases by using antibodies that target or block effector molecules. Indeed, Yajun Guo at Chinese Military General Hospital presented the clinical application of targeted immunotherapy for cancer by antibody.
Given the promising results from recent clinical trials, targeting on Tregs and other T effectors will become an important trend in clinic application of immunotherapy in treating human diseases. We look forward to hearing more exciting progress in next conference that will be held in 2 years.
